Research Paper Volume 13, Issue 20 pp 23726—23738

Figure 5. MiR-181b-5p targets SCD1 in ovarian cancer cells. (A) The binding of miR-181b-5p and SCD1 3’ UTR was analyzed by bioinformatic analysis based on Targetscan (http://www.targetscan.org/vert_72/). (B–D) The TOV-21G and SKOV-3 cells were treated with control mimic or miR-181b-5p mimic. (B) The luciferase activities of wild type SCD1 (SCD1 WT) and SCD1 with the miR-181b-5p-binding site mutant (SCD1 MUT) were determined by luciferase reporter gene assays in the cells. (C, D) The mRNA expression of SCD1 was tested by qPCR assays in the cells. (E, F) The protein expression of SCD1 was measured by Western blot analysis in the cells. The TOV-21G and SKOV-3 cells were treated with control shRNA or SOX2-OT shRNA, co-treated with SOX2-OT shRNA and miR-181b-5p inhibitor. The protein expression of SCD1 was analyzed by Western blot analysis in the cells. Data are presented as mean ± SD. Statistic significant differences were indicated: * P < 0.05, ** P < 0.01.